Document is current

Article History

Received: 7 September 2023

Accepted: 29 January 2024

First Online: 6 February 2024

Declarations

:

: The University of Toronto (U of T) Research Ethics Boards (REBs), Health Sciences REB (ethics@utoronto.ca) reviewed and approved/designated the project as a quality improvement project. All methods were performed in accordance with the relevant guidelines and regulations set out by the University of Toronto (U of T) Research Ethics Boards (REBs), Health Sciences REB (research.utoronto.ca). An informed consent statement was not required to be submitted for approval by the University of Toronto (U of T) Research Ethics Boards (REBs), Health Sciences REB ((ethics@utoronto.ca or 416-978- 7248) as they designated the project as a quality improvement project.

: Not applicable.

: PS competing interests are as follows.

: CAMH, Health Canada, Ontario Ministry of Health and Long-Term Care, Canadian Institutes of Health Research, Canadian Centre on Substance Abuse, Public Health Agency of Canada, Pfizer Inc./Canada, Ontario Lung Association, Medical Psychiatry Alliance, ECHO, Canadian Cancer Society Research Institute, Cancer Care Ontario, Ontario Institute Cancer Research, Ontario Brain Institute, McLaughlin Centre, Alternate Funding Plans for Academic Health Science Centres, Workplace Safety Insurance Board, National Institutes of Health, Association of Faculties of Medicine of Canada, Shoppers Drug Mart, Bhasin Consulting Fund Inc., Patient-Centered Outcomes Research Institute.

: Pfizer Canada Inc., ABBVie, Bristol-Myers Squibb.

: Pfizer Canada Inc., Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Inflexxion Inc., V-CC Systems Inc., MedPlan Communications, Kataka Medical Communications, Miller Medical Communications, NVision Insight Group, Sun Life Financial, Myelin & Associates.

: Johnson & Johnson, Novartis, Pfizer Inc. MAO was a paid consultant on the Project for part of the time.